数据
资源
版本对比
免费注册
预约演示
免费注册
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for
RYBREVANT
®
2023-09-06
·
BioSpace
临床结果
临床3期
临床2期
引进/卖出
上市批准
MARIPOSA-2 is the first Phase 3 study to show statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the post-
osimertinib
setting MARIPOSA-2 is the second
RYBREVANT
® Phase 3 study to show the potential to improve outcomes in patients with
EGFR-mutated non-small cell lung cancer (NSCLC)
RARITAN, N.J., Sept. 6, 2023 /PRNewswire/ -- The
Janssen Pharmaceutical Inc.
Companies of
Johnson & Johnson
today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating
RYBREVANT
® (
amivantamab-vmjw
), a bispecific antibody targeting
epidermal growth factor receptor (EGFR)
and mesenchymal-epithelial transition (MET), given with and without
lazertinib
, an oral, third-generation EGFR tyrosine kinase inhibitor (TKI), combined with chemotherapy (
carboplatin
and
pemetrexed
) versus chemotherapy alone. MARIPOSA-2 enrolled patients with locally advanced or metastatic
EGFR
exon 19 deletions (ex19del) or L858R substitution
NSCLC
after disease progression on or after
osimertinib
. The study met its dual primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS versus chemotherapy alone in both experimental treatment arms. No new safety signals were found for the addition of
RYBREVANT
® to chemotherapy.1
Janssen
plans to submit these results for presentation at upcoming scientific congresses, including details on secondary endpoints such as overall survival (OS), objective response, duration of response (DoR) and intracranial PFS. "MARIPOSA-2 provides the first Phase 3 study data of
RYBREVANT
-based regimens in the broader
EGFR
-mutated non-small cell lung cancer population," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology,
Janssen Research & Development, LLC
. "The study builds on the significant innovation of
RYBREVANT
, a first-in-class bispecific antibody targeting two major oncogenic driver pathways, with clinically meaningful results that may change the treatment paradigm." MARIPOSA-2 (NCT04988295) is a randomized, open-label Phase 3 study evaluating the efficacy and safety of two regimens of
RYBREVANT
® (with and without
lazertinib
) and chemotherapy. Patients with locally advanced or metastatic
EGFR
ex19del or L858R substitution
NSCLC
who had disease progression on or after
osimertinib
were randomized to treatment with
RYBREVANT
® plus chemotherapy,
RYBREVANT
® plus chemotherapy with
lazertinib
, or chemotherapy alone. The dual primary endpoint was used to compare the PFS (using RECIST v1.1 guidelines*) as assessed by blinded independent central review (BICR) for each experimental arm to chemotherapy alone. Secondary endpoints included objective response as assessed by BICR, OS, DoR, time to subsequent therapy, PFS after first subsequent therapy (PFS2) and intracranial PFS. All study participants underwent serial brain imaging to allow for the robust assessment of intracranial endpoints, and to assess the central nervous system (CNS) activity of
RYBREVANT
® with and without
lazertinib
. As brain metastases can lead to significant burden and poor outcomes for patients, this aspect of the study design provides critical information in an area of high unmet need. The study enrolled 657 patients with locally advanced or metastatic
EGFR
ex19del or
L858R substitution NSCLC
who had disease progression on or after
osimertinib.1
A
RYBREVANT
® and
lazertinib
combination is also being evaluated in the first-line setting for patients with
EGFR
-
mutated NSCLC
in the pivotal Phase 3
MARIPOSA
study.
MARIPOSA
is comparing the combination therapy of
RYBREVANT
® and
lazertinib
head-to-head versus
osimertinib
, in addition to a third arm of
lazertinib
to assess the contribution of components. About
RYBREVANT
®
RYBREVANT
® (
amivantamab-vmjw
), a fully-human bispecific antibody targeting
EGFR
and
MET
with immune cell-directing activity, received accelerated approval by the
U.S. Food and Drug Administration (FDA)
in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with
EGFR
exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.2 This indication is approved under accelerated approval based on overall response rate and DoR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
RYBREVANT
® has also received approval from health authorities in Europe, as well as other markets around the world. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
Non-Small Cell Lung Cancer
◊ prefer NGS-based strategies over PCR-based approaches for the detection of
EGFR exon 20
insertion variants and include
amivantamab
-vmjw (
RYBREVANT
®) as a subsequent therapy option with a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without immunotherapy and have
EGFR exon 20
insertion mutation-positive advanced NSCLC.3†^ In addition to the Phase 3 MARIPOSA-2 study,
RYBREVANT
® is being studied in multiple clinical trials in
NSCLC
, including: The Phase 3
MARIPOSA
(NCT04487080) study assessing
RYBREVANT
® in combination with
lazertinib
versus
osimertinib
and versus
lazertinib
alone in the first-line treatment of patients with locally advanced or metastatic NSCLC with
EGFR
ex19del or L858R substitution mutations.4 The Phase 3 PAPILLON (NCT04538664) study assessing
RYBREVANT
® in combination with
carboplatin
-
pemetrexed
versus chemotherapy alone in the first-line treatment of patients with
advanced or metastatic NSCLC
with
EGFR exon 20
insertion mutations. Topline data for this randomized Phase 3 study demonstrated statistically significant and clinically meaningful improvement in PFS in patients receiving
RYBREVANT
®.5 The Phase 1 CHRYSALIS (NCT02609776) study evaluating
RYBREVANT
® in participants with
advanced NSCLC.6
The Phase 1/1b CHRYSALIS-2 (NCT04077463) study evaluating
RYBREVANT
® in combination with
lazertinib
and
lazertinib
as a monotherapy in patients with
advanced NSCLC
with
EGFR
mutations.7 The Phase 1 PALOMA (NCT04606381) study assessing the feasibility of subcutaneous (SC) administration of
amivantamab
based on safety and pharmacokinetics and to determine a dose, dose regimen and formulation for
amivantamab
SC delivery.8 The Phase 2 PALOMA-2 (NCT05498428) study assessing subcutaneous
amivantamab
in participants with
advanced or metastatic solid tumors
including
EGFR
-mutated NSCLC.9 The Phase 3 PALOMA-3 (NCT05388669) study assessing
lazertinib
with subcutaneous
amivantamab
compared to intravenous
amivantamab
in participants with
EGFR
-mutated advanced or metastatic
NSCLC.10
The Phase 1/2 METalmark (NCT05488314) study assessing
RYBREVANT
® and
capmatinib
combination therapy in locally advanced or metastatic NSCLC.11 The Phase 1/2 PolyDamas (NCT05908734) study assessing
RYBREVANT
® and
cetrelimab
combination therapy in locally advanced or metastatic NSCLC.12 The Phase 2 SKIPPirr study (NCT05663866) exploring how to decrease the incidence and/or severity of first-dose infusion-related reactions with
RYBREVANT
® in combination with
lazertinib
in relapsed or refractory
EGFR
-mutated advanced or metastatic NSCLC.13 For more information, visit: . About
Lazertinib
Lazertinib
is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating
EGFR
mutations while sparing wild type-
EGFR
. An analysis of the efficacy and safety of
lazertinib
from the Phase 3 study was published in The Journal of Clinical Oncology in 2023.14 In 2018,
Janssen Biotech, Inc.
, entered into a license and collaboration agreement with
Yuhan Corporation
for the development of
lazertinib
. About
Non-Small Cell Lung Cancer
Worldwide,
lung cancer
is one of the most common
cancers
, with
NSCLC
making up 80 to 85 percent of all
lung cancer
cases.15,16 The main subtypes of
NSCLC
are
adenocarcinoma
,
squamous cell carcinoma
and
large cell carcinoma.17
Among the most common driver mutations in
NSCLC
are alterations in
EGFR
, which is a receptor tyrosine kinase controlling cell growth and division.18
EGFR
mutations are present in 10 to 15 percent of Western patients with
NSCLC
with
adenocarcinoma
histology and occur in 40 to 50 percent of Asian patients.17,18,19,20,21,22,23
EGFR
ex19del or
EGFR
L858R mutations
are the most common
EGFR
mutations.24 The five-year survival rate for all people with
advanced NSCLC
and
EGFR
mutations treated with
EGFR TKIs
is less than 20 percent.25,26 Patients with
EGFR
ex19del or L858R mutations have a real-world five-year OS of 19 percent.27 Brain metastases are a common complication in a wide range of
cancers
, but they are particularly common among patients with
EGFR
-
mutated lung cancer.28
Approximately 20 percent of newly diagnosed patients with
EGFR
-
mutated advanced NSCLC
have brain metastases at diagnosis and risk of developing new metastases rise over time.28,29,30 Targeted systemic treatments in patients with
EGFR
-
mutated NSCLC
have CNS penetrance but, currently, clinical trials of systemic treatments largely exclude patients with brain metastases that have not been irradiated or surgically removed and the need for more therapeutic options is desired.28,31
RYBREVANT
® IMPORTANT SAFETY INFORMATION2 WARNINGS AND PRECAUTIONS Infusion-Related Reactions
RYBREVANT
® can cause
infusion-related reactions (IRR)
; signs and symptoms of IRR include
dyspnea
,
flushing
,
fever
, chills,
nausea
,
chest discomfort
,
hypotension
, and
vomiting
. Based on the safety population, IRR occurred in 66% of patients treated with
RYBREVANT
®. Among patients receiving treatment on Week 1 Day 1, 65% experienced an IRR, while the incidence of IRR was 3.4% with the Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRRs, 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62% and 1.3% of patients permanently discontinued
RYBREVANT
® due to IRR. Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse
RYBREVANT
® as recommended. Administer
RYBREVANT
® via a peripheral line on Week 1 and Week 2. Monitor patients for any signs and symptoms of infusion reactions during
RYBREVANT
® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue
RYBREVANT
® based on severity.
Interstitial Lung Disease
/
Pneumonitis
RYBREVANT
® can cause
interstitial lung disease (ILD)/pneumonitis
. Based on the safety population,
ILD
/
pneumonitis
occurred in 3.3% of patients treated with
RYBREVANT
®, with 0.7% of patients experiencing Grade 3
ILD
/
pneumonitis
. Three patients (1%) discontinued
RYBREVANT
® due to
ILD
/
pneumonitis
. Monitor patients for new or worsening symptoms indicative of
ILD
/
pneumonitis
(e.g.,
dyspnea
,
cough
,
fever
). Immediately withhold
RYBREVANT
® in patients with suspected
ILD
/
pneumonitis
and permanently discontinue if
ILD
/
pneumonitis
is confirmed. Dermatologic Adverse Reactions
RYBREVANT
® can cause
rash
(including
dermatitis acneiform
),
pruritus
and
dry skin
. Based on the safety population,
rash
occurred in 74% of patients treated with
RYBREVANT
®, including
Grade 3 rash
in 3.3% of patients. The median time to onset of
rash
was 14 days (range: 1 to 276 days).
Rash
leading to dose reduction occurred in 5% of patients, and
RYBREVANT
® was permanently discontinued due to
rash
in 0.7% of patients.
Toxic epidermal necrolysis
occurred in one patient (0.3%) treated with
RYBREVANT
®. Instruct patients to limit sun exposure during and for 2 months after treatment with
RYBREVANT
®. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen. Alcohol-free emollient cream is recommended for dry skin. If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe
rash
, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. Withhold, dose reduce or permanently discontinue
RYBREVANT
® based on severity. Ocular Toxicity
RYBREVANT
® can cause ocular toxicity including
keratitis
,
dry eye symptoms
,
conjunctival redness
, blurred vision,
visual impairment
,
ocular itching
, and
uveitis
. Based on the safety population,
keratitis
occurred in 0.7% and
uveitis
occurred in 0.3% of patients treated with
RYBREVANT
®. All events were Grade 1-2. Promptly refer patients presenting with eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue
RYBREVANT
® based on severity. Embryo-Fetal Toxicity Based on its mechanism of action and findings from animal models,
RYBREVANT
® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of
RYBREVANT
®. Adverse Reactions The most common adverse reactions (≥20%) were
rash
(84%), IRR (64%),
paronychia
(50%),
musculoskeletal pain
(47%),
dyspnea
(37%),
nausea
(36%),
fatigue
(33%),
edema
(27%),
stomatitis
(26%),
cough
(25%),
constipation
(23%), and
vomiting
(22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased
alkaline phosphatase
(4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%). Please read the full Prescribing Information for
RYBREVANT
®. About the
Janssen Pharmaceutical Companies
of
Johnson & Johnson
At
Janssen
, we're creating a future where disease is a thing of the past. We're the
Pharmaceutical Companies
of
Johnson & Johnson
, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology;
Infectious Diseases
& Vaccines;
Neuroscience
;
Oncology
; and
Pulmonary Hypertension
. Learn more at . Follow us at @JanssenGlobal and @JanssenUS.
Janssen Research & Development, LLC
and
Janssen Biotech, Inc.
, are part of the
Janssen Pharmaceutical Companies
of
Johnson & Johnson
. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of
RYBREVANT
® (
amivantamab-vmjw
) and
lazertinib
. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Janssen Research and Development, LLC
,
Janssen Biotech, Inc.
, any of the other
Janssen Pharmaceutical Companies
and/or
Johnson & Johnson
. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in
Johnson & Johnson
's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in
Johnson & Johnson
's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from
Johnson & Johnson
. None of
Janssen Research and Development, LLC
,
Janssen Biotech, Inc.
, the
Janssen Pharmaceutical Companies
nor
Johnson & Johnson
undertakes to update any forward-looking statement as a result of new information or future events or developments. *RECIST (version 1.1) refers to Response Evaluation Criteria in
Solid Tumors
, which is a standard way to measure how well
solid tumors
respond to treatment and is based on whether
tumors
shrink, stay the same or get bigger. ◊The NCCN Content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no representations or warranties and explicitly disclaims the appropriateness or applicability of the NCCN Content to any specific patient's care or treatment. †See the NCCN Guidelines for detailed recommendations, including other treatment options. ^The NCCN Guidelines for
NSCLC
provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories. 1 ClinicalTrials.gov. A Study of
Amivantamab
and
Lazertinib
in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With
Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
After
Osimertinib
Failure (MARIPOSA-2). Available at: . Accessed July 2023. 2
RYBREVANT
® Prescribing Information. Horsham, PA:
Janssen Biotech, Inc.
3 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
Non-Small Cell Lung Cancer
V.3.2022. © National Comprehensive
Cancer
Network, Inc. 2022. All rights reserved. Accessed March 22, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 4 ClinicalTrials.gov. A Study of
Amivantamab
and
Lazertinib
Combination Therapy Versus
Osimertinib
in
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
(MARIPOSA) Available at: . Accessed July 2023. 5 ClinicalTrials.gov. A Study of Combination
Amivantamab
and
Carboplatin-Pemetrexed
Carboplatin-Pemetrexed
Therapy, Compared With
Carboplatin
-
Pemetrexed
, in Participants With
Advanced or Metastatic Non-Small Cell Lung Cancer
Characterized by
Epidermal Growth Factor Receptor (EGFR)
Exon 20 Insertions (PAPILLON). Available at: . Accessed July 2023. 6 ClinicalTrials.gov. A Study of
Amivantamab
, a Human Bispecific
EGFR
and cMet Antibody
, in Participants With
Advanced Non-Small Cell Lung Cancer
(CHRYSALIS). Available at: . Accessed July 2023. 7 ClinicalTrials.gov. A Study of
Lazertinib
as Monotherapy or in Combination With
Amivantamab
in Participants With
Advanced Non-small Cell Lung Cancer
(CHRYSALIS-2). Available at: . Accessed July 2023. 8 ClinicalTrials.gov. A Study of
Amivantamab
Subcutaneous (SC) Administration for the Treatment of
Advanced Solid Malignancies
(PALOMA). Available at: . Accessed May 2023. 9 ClinicalTrials.gov. A Study of
Amivantamab
in Participants With
Advanced or Metastatic Solid Tumors
Including
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
(PALOMA-2). Available at: . Accessed July 2023. 10 ClinicalTrials.gov. A Study of
Lazertinib
With Subcutaneous
Amivantamab
Compared With Intravenous
Amivantamab
in Participants With
Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
(PALOMA-3). Available at: . Accessed July 2023. 11 ClinicalTrials.gov. A Study of
Amivantamab
and
Capmatinib
Combination Therapy in
Unresectable Metastatic Non-small Cell Lung Cancer
(METalmark). Available at: . Accessed July 2023. 12 ClinicalTrials.gov. A Study of Combination Therapy With
Amivantamab
and
Cetrelimab
in Participants With
Metastatic Non-small Cell Lung Cancer
(PolyDamas). Available at: . Accessed July 2023. 13 ClinicalTrials.gov. Premedication to Reduce
Amivantamab
Associated Infusion Related Reactions (SKIPPirr). Available at: . Accessed July 2023. 14 Cho, BC, et al. (2023).
Lazertinib
versus
gefitinib
as first-line treatment in patients with
EGFR
-
mutated advanced non-small-cell lung cancer
: Results From LASER301. J Clin Oncol. JCO2300515. Advance online publication. . 15 The World Health Organization. Cancer. . Accessed July 2023. 16 American
Cancer
Society. What is
Lung Cancer
? . Accessed July 2023. 17 Oxnard JR, et al. Natural history and molecular characteristics of
lung cancers
harboring
EGFR
exon 20 insertions. J Thorac Oncol. 2013;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18. 18 Bauml JM, et al. Underdiagnosis of
EGFR
Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on
Lung Cancer
Annual Meeting; January 29, 2021; Singapore. 19 Riess JW, et al. Diverse
EGFR
exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of
NSCLC
. J Thorac Oncol. 2018;13(10):1560-1568. doi:10.1016/j.jtho.2018.06.019. 20 Pennell NA, et al. A phase II trial pf adjuvant
erlotinib
in patients with resected
epidermal growth factor receptor-mutant non-small cell lung cancer
epidermal growth factor receptor
-mutant non-small cell lung cancer. J Clin Oncol. 2019;37(2):97-104. 21 Burnett H, et al. Epidemiological and clinical burden of
EGFR exon 20
insertion in
advanced non-small cell lung cancer
: a systematic literature review. Abstract presented at: World Conference on
Lung Cancer
Annual Meeting; January 29, 2021; Singapore. 22 Zhang YL, et al. The prevalence of
EGFR
mutation in patients with
non-small cell lung cancer
: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. 23 Midha A, et al.
EGFR
mutation incidence in
non-small-cell lung cancer
of
adenocarcinoma
histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911. 24 American Lung Association.
EGFR
and
Lung Cancer
. . Accessed July 2023. 25 Howlader N, et al. SEER
Cancer
Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, , based on November 2018 SEER data submission, posted to the SEER web site. 26 Lin JJ, et al. Five-year survival in
EGFR-mutant metastatic lung adenocarcinoma
treated with
EGFR-TKIs
. J Thorac Oncol. 2016;11(4):556-65. 27 Girard N, et al. Comparative clinical outcomes for patients with
NSCLC
harboring
EGFR exon 20
insertion mutations and common
EGFR
mutations. Abstract presented at: World Conference on
Lung Cancer
Annual Meeting; January 29, 2021; Singapore. 28 Kelly, WJ, et al. (2018). Management of brain metastases in
epidermal growth factor receptor mutant non-small-cell lung cancer
epidermal growth factor receptor
mutant non-small-cell lung cancer. Front Oncol. 29 Barnholtz-Sloan JS, et al. Incidence proportions of
brain metastases
in patients diagnosed (1973 to 2001) in the Metropolitan Detroit
Cancer
Surveillance System. J Clin Oncol. 2004;22(14):2865–72. . 30 Schouten LJ, et al. Incidence of brain metastases in a cohort of patients with
carcinoma
of the breast, colon, kidney, and lung and
melanoma
. Cancer. 2002;94(10):2698–705. . 31 Page S, et al. Systemic treatment of brain metastases in
non-small cell lung cancer
. Eur J
Cancer
. 2020;(132):187–198. Jackie Zima-Evans +1 215-534-2973 Investor Relations: Raychel Kruper investor-relations@its.jnj.com U.S. Medical Inquiries: +1 800-526-7736
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Janssen Pharmaceuticals, Inc.
Johnson & Johnson
Janssen
[+7]
适应症
角膜炎
晚期恶性实体瘤
肿瘤
[+42]
靶点
EGFR
c-Met
EGFR exon 20
[+2]
药物
埃万妥珠单抗
甲磺酸奥希替尼
甲磺酸兰泽替尼
[+8]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务